A landmark study has pinpointed a previously unknown molecular driver behind hypertrophic cardiomyopathy (HCM), the most common inherited heart disease and a notorious cause of sudden cardiac arrest in young athletes. The research, conducted by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and published in Nature Cardiovascular Research, not only deciphers this new pathogenic pathway but also delivers robust evidence that the breakthrough drug mavacamten works effectively against it, broadening the therapeutic horizon for affected families.
For decades, the narrative of HCM has centered on the sarcomere, the fundamental contractile unit of cardiac muscle. Mutations in the MYBPC3 gene, which encodes cardiac myosin binding protein C (cMyBP-C), are among the most frequent culprits. While most known mutations cause disease by simply slashing the levels of this critical protein, a distinct subset of mutations allows normal protein expression but corrupts its function. The precise mechanism by which these “point mutations” trigger the characteristic hypercontractility and thickening of the left ventricle had remained an enigma until now.
By engineering a mouse model carrying the specific R502W variant of cMyBP-C, the CNIC team, led by Dr. Jorge Alegre Cebollada and first author Laura Sen Martín, was able to dissect the atomic-level dysfunction. They discovered that the mutation disrupts a vital molecular handshake between cMyBP-C and myosin, the motor protein that generates force with every heartbeat. Under normal physiology, cMyBP-C acts as a molecular brake, tethering myosin heads and limiting their interaction with actin filaments during diastole. The R502W mutation weakens this regulatory grip, effectively releasing the brakes on the myosin motor. This results in excessive cross-bridge formation, driving the pathological hypercontractility and impaired relaxation that defines HCM.
This mechanistic insight proved crucial for understanding the variable responses to mavacamten, the first-in-class allosteric modulator of cardiac myosin. Mavacamten works by stabilizing the myosin motor in an energy-sparing, off-state, quieting the excessive sarcomere activity. The study demonstrated that in the R502W model, characterized by a gain-of-function hypercontractility at the motor level, mavacamten directly corrected the mechanical defect, restoring exercise tolerance to a degree not seen in models driven by simple protein insufficiency.
Further validation came from a truly translational platform: cardiac microtissues engineered from human induced pluripotent stem cell-derived cardiomyocytes harboring the R502W mutation. When these tissues, which faithfully replicate the super-contractile phenotype of the disease, were exposed to mavacamten, the excessive force generation was normalized. This bridging of the mouse model to human engineered tissue provides a powerful preclinical testament to the drug’s ability to tame the molecular hyperexcitability regardless of the genetic fine print.
The findings carry a transformative message for precision cardiology. Clinicians have observed that not all HCM patients respond identically to mavacamten, raising questions about resistance mechanisms tied to specific genotypes. However, the CNIC study suggests that the variable effectiveness is not a simple function of the mutation’s identity but rather its physiological consequence. Since mavacamten acts on the final common pathway of sarcomeric overactivation, it appears broadly effective whether the underlying cause is a protein deficiency or a specific modification that alters myosin kinetics. This dismantles the assumption that certain missense mutations might be inherently resistant to therapy. The research also establishes the R502W mouse line as an invaluable platform for preclinical trials, especially to investigate early intervention strategies before irreversible fibrosis sets in, a question that remains a clinical blind spot. As the field moves toward a future of gene editing and molecular therapies, this study clearly defines the myosin-cMyBP-C interface as a hypersensitive control point for cardiac mechanics, solidifying the logic behind drugs that can pharmacologically mimic the lost molecular brake.
Subject of Research: People and animal models
Article Title: Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy
News Publication Date: 7-Jul-2026
Web References: http://dx.doi.org/10.1038/s44161-026-00833-3
References: Nature Cardiovascular Research
Image Credits: CNIC
Keywords
Hypertrophic cardiomyopathy, MYBPC3, Mavacamten, Cardiac myosin binding protein C, Sarcomere mechanics, Sudden cardiac death, Inherited heart disease, CNIC, Genetic mutation, Molecular brake
